Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$27,000.00

Menopause and brain aging: Investigating the link of postmenopausal estradiol, hormone therapy, and Alzheimer’s disease risk markers.

FY 2024-25

Summary
Females have a three-fold greater risk of developing Alzheimer’s disease (AD) compared to males. This disparity is attributed to the longer life expectancy in females, as age is the strongest predictor of dementia. However, emerging evidence suggests that menopause-related estradiol (E2) decline may also play a significant role. E2, a sex hormone that may protect against neurodegeneration, declines sharply during menopause. This drop may represent a period of greater susceptibility to AD. While E2-based hormone therapies (HT) can stabilize E2, links with AD and quality of life (QoL) remain inconsistent. Additionally, the association of E2 and other AD risk markers, such as cognition, behaviour, and function, and the buildup of biological markers like amyloid-beta (AB) and phosphorylated tau (p-tau), is poorly understood. This project will determine how post-menopause E2 levels are linked to clinical features and biomarkers of AD, and also determine the relationship between HT use and QoL. We will recruit 100 postmenopausal females from women’s health clinics, clinical networks, and other cohort studies. Participants will complete assessments of medical and fertility history, cognition, behaviour, function, and QoL. Blood samples will be collected to measure E2, AB, and p-tau levels. Regressions will model cross-sectional associations between E2 levels and clinical and biomarker outcomes, and HT use with QoL. Identifying at-risk females in post-menopause, well before clinical AD symptoms emerge, may reveal a critical window for prevention. This research will determine whether post-menopause E2 represents an opportunity for early intervention, with the potential to improve the outcomes of menopausal females at risk of AD.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529798
Name
Crockford Jasper F
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Menopause and brain aging: Investigating the link of postmenopausal estradiol, hormone therapy, and Alzheimer’s disease risk markers.
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Behaviour; Biomarkers; Cognition; Dementia; Estradiol; Function; Hormone Therapy; Menopause; Women'S Health
Abstract
Females have a three-fold greater risk of developing Alzheimer’s disease (AD) compared to males. This disparity is attributed to the longer life expectancy in females, as age is the strongest predictor of dementia. However, emerging evidence suggests that menopause-related estradiol (E2) decline may also play a significant role. E2, a sex hormone that may protect against neurodegeneration, declines sharply during menopause. This drop may represent a period of greater susceptibility to AD. While E2-based hormone therapies (HT) can stabilize E2, links with AD and quality of life (QoL) remain inconsistent. Additionally, the association of E2 and other AD risk markers, such as cognition, behaviour, and function, and the buildup of biological markers like amyloid-beta (AB) and phosphorylated tau (p-tau), is poorly understood. This project will determine how post-menopause E2 levels are linked to clinical features and biomarkers of AD, and also determine the relationship between HT use and QoL. We will recruit 100 postmenopausal females from women’s health clinics, clinical networks, and other cohort studies. Participants will complete assessments of medical and fertility history, cognition, behaviour, function, and QoL. Blood samples will be collected to measure E2, AB, and p-tau levels. Regressions will model cross-sectional associations between E2 levels and clinical and biomarker outcomes, and HT use with QoL. Identifying at-risk females in post-menopause, well before clinical AD symptoms emerge, may reveal a critical window for prevention. This research will determine whether post-menopause E2 represents an opportunity for early intervention, with the potential to improve the outcomes of menopausal females at risk of AD.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Crockford, Jasper F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~